Login
Products
Login
Home
Alerts
Search
Watchlists
Products

Fermenta Biotech Ltd

FERMENTA
BSE
337.25
2.87%
Last Updated:
02 Apr '26, 3:59 PM
Company Overview
Alert
Watchlist
Note

Fermenta Biotech Ltd

FERMENTA
BSE
337.25
2.87%
02 Apr '26, 3:59 PM
Company Overview
Add Alert
Add to Watchlist
Edit Note
6M
Price
Charts
Documents

Quick Ratios

Edit Ratios
Mkt Cap
Market Capitalization
993Cr
Close
Close Price
337.25
Industry
Industry
Pharma - API
PE
Price To Earnings
11.30
PS
Price To Sales
1.83
Revenue
Revenue
544Cr
Rev Gr TTM
Revenue Growth TTM
27.34%
PAT Gr TTM
PAT Growth TTM
136.42%

Quarterly Results

Consolidated
Standalone
Numbers
Percentage
QuarterMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Revenue
RevenueCr
105825799977895156140136130137
Growth YoY
Revenue Growth YoY%
9.4-10.3-42.080.4-7.4-5.267.058.143.774.437.0-12.2
Expenses
ExpensesCr
86727174927776103103108104112
Operating Profit
Operating ProfitCr
1911-142551195337282725
OPM
OPM%
18.313.3-24.525.45.51.019.834.026.420.720.518.2
Other Income
Other IncomeCr
-82-6353324951
Interest Expense
Interest ExpenseCr
654533443333
Depreciation
DepreciationCr
666666666655
PBT
PBTCr
-12-29161-6124532282417
Tax
TaxCr
40068017-1665
PAT
PATCr
-52-2910-7-6113833221812
Growth YoY
PAT Growth YoY%
-168.5185.3-243.6126.5-35.0-368.3138.3279.3566.7464.362.1-68.3
NPM
NPM%
-5.02.7-51.110.1-7.3-7.611.724.223.815.813.88.8
EPS
EPS
-1.40.6-7.33.4-2.4-2.03.912.711.87.56.24.4

Profit & Loss

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Revenue
RevenueCr
142153164302403292377399350336469544
Growth
Revenue Growth%
8.26.984.233.6-27.729.35.6-12.2-4.139.915.8
Expenses
ExpensesCr
126135152209255226296337332308360427
Operating Profit
Operating ProfitCr
161912931496582611828110117
OPM
OPM%
11.212.37.330.836.922.421.615.45.08.223.421.5
Other Income
Other IncomeCr
0339121288-2041219
Interest Expense
Interest ExpenseCr
5610142119181721171412
Depreciation
DepreciationCr
9810121215202628252422
PBT
PBTCr
37-676129435227-51-1083102
Tax
TaxCr
2432111-16912214717
PAT
PATCr
13-855118604315-53-247685
Growth
PAT Growth%
184.4-403.4766.3115.0-49.5-28.5-64.6-452.854.8418.211.2
NPM
NPM%
0.71.8-5.018.129.220.411.33.8-15.2-7.216.315.6
EPS
EPS
0.2-0.4-4.23.113.620.615.85.3-17.7-5.426.429.8

Balance Sheet

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital
Equity CapitalCr
2222514141414141515
Reserves
ReservesCr
129128142124246295346358301274348376
Current Liabilities
Current LiabilitiesCr
9410886104156195209207209173212224
Non Current Liabilities
Non Current LiabilitiesCr
142449146145110117128115894442
Total Liabilities
Total LiabilitiesCr
262288308387551614687707637548614651
Current Assets
Current AssetsCr
9195104182296284310314253242335336
Non Current Assets
Non Current AssetsCr
171194204204256330377393383306279315
Total Assets
Total AssetsCr
262288308387551614687707637548614651

Cash Flow

Consolidated
Standalone
Financial YearMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Operating Cash Flow
Operating Cash FlowCr
1572599034634311610541
Investing Cash Flow
Investing Cash FlowCr
-18-157-101-97-44-42-26-55-160
Financing Cash Flow
Financing Cash FlowCr
110-128912-47-1-22-41-91-51
Net Cash Flow
Net Cash FlowCr
-21-4476-5720-419-1-10
Free Cash Flow
Free Cash FlowCr
-20-23-174255-3476768638
CFO To PAT
CFO To PAT%
1,579.9240.1-23.2108.176.657.9147.2288.4-218.5-438.853.5
CFO To EBITDA
CFO To EBITDA%
94.834.616.063.760.752.876.770.7659.5382.937.3

Ratios

Consolidated
Standalone
Financial YearMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
136160176654755626737605315446805
Price To Earnings
Price To Earnings
595.00.00.019.46.410.315.938.50.00.010.4
Price To Sales
Price To Sales
1.01.01.12.21.92.11.91.50.91.31.7
Price To Book
Price To Book
1.01.21.25.33.02.02.01.61.01.52.2
EV To EBITDA
EV To EBITDA
9.410.821.08.55.812.311.313.227.019.17.7
Profitability Ratios
Profitability Ratios
GPM
GPM%
55.658.358.473.677.172.964.461.656.161.268.6
OPM
OPM%
11.212.37.330.836.922.421.615.45.08.223.4
NPM
NPM%
0.71.8-5.018.129.220.411.33.8-15.2-7.216.3
ROCE
ROCE%
4.67.42.030.733.512.111.77.2-5.71.720.4
ROE
ROE%
0.72.1-5.743.447.119.211.84.0-16.9-8.321.1
ROA
ROA%
0.40.9-2.714.221.49.76.22.1-8.3-4.412.4
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
### **Company Overview** Fermenta Biotech Ltd. (FBL), formerly known as DIL Ltd., is a leading Indian multinational biotechnology company with a 74-year legacy (founded in 1951). Headquartered in Thane, Maharashtra, Fermenta operates at the intersection of **pharmaceuticals, nutrition, green chemistry, and environmental solutions**. The company is recognized globally as one of the **top three manufacturers of Vitamin D3 API**, and it is **India’s only manufacturer** of this critical nutrient. Through a strategic transformation post the 2019 merger of DIL and Fermenta Biotech Limited, the company has evolved from a traditional API player into a science-driven, integrated nutrition and biotech solutions provider with a resilient, diversified business model. --- ### **Core Business Segments** Fermenta operates across four primary verticals: 1. **Nutrition** - Flagship product: **Vitamin D3** in multiple forms (crystalline, oil, cold water dispersible, spray-dried powder) for human and animal nutrition. - Key innovations: - **VITADEE™ Green**: World’s first **plant-based, vegan-compliant Vitamin D3** derived from phytosterols (patented Indian process), meeting multi-compendial standards and offering superior stability. - **VITADEE™ 100 SD**: 100,000 IU/g **pharmaceutical-grade spray-dried Vitamin D3** with **CEP certification from EDQM**, enabling access to regulated European markets. - Expanding portfolio: **Vitamin K1** (API USP and 5% spray-dried powder), **Fortified Rice Kernels (FRK)**, **Vitamin AD2** for oil fortification, and **custom nutritional premixes**. - Leadership in **nutritional ingredient innovation** for preventive health, addressing immunity, bone health, and micronutrient deficiency. 2. **APIs & Intermediates** - Manufactures **Phenyramidol HCl** (muscle relaxant) and **Activated Dimethicone Powder** (anti-flatulent API) for global pharmaceutical customers. - R&D focus on **calcifediol**, **cholesterol synthesis**, and **niche APIs**. - Innovations in green chemistry: **patented enzymatic synthesis of Molnupiravir**, an antiviral used in COVID-19 treatment. 3. **Green Chemistry & Enzymes** - Pioneer in **immobilized enzyme technology** in India. - Key enzyme products: - **Fermase PA 850 & PS 250**: Penicillin G Amidase (PGA) enzymes for beta-lactam antibiotic synthesis (ampicillin, amoxicillin). - **CAL B Lipase**: High-performance enzyme for green chemistry applications (chiral APIs, biofuels, oleochemicals, personal care). - Enzymes used in **APIs, food, fragrances, biodiesel, and diagnostics**. 4. **Environmental Solutions** - Provides **end-to-end biotech-based water and wastewater treatment** solutions. - Services include **engineering, procurement, construction (EPC), STP/ETP operation**, and **maintenance contracts**. - Proprietary product: **Fermsept®**, an eco-friendly microbial enhancer for efficient waste treatment. - In October 2025, Fermenta transferred its environmental business to **Fermenta Environment Solutions Private Limited (FESPL)** via a slump sale to enable focused growth and operational excellence. --- ### **Manufacturing & R&D Infrastructure** - **State-of-the-art manufacturing plants**: - **Kullu, Himachal Pradesh**: Enzymes, Vitamin D3, APIs, and customized premixes. - **Dahej, Gujarat**: Dedicated Vitamin D3 and fish oil cholesterol facility with **US FDA** and **EU GMP** certifications. - **Tirupati, Andhra Pradesh**: Fortified Rice Kernels (FRK) manufacturing. - **R&D Excellence Centre**: Located in **Thane, Maharashtra**, DSIR-approved with capabilities in: - Multi-step organic synthesis - Photochemistry and chromatography (API R&D) - Fermentation, enzyme immobilization, and biocatalysis - Formulation development for liquid and solid premixes --- ### **Global Presence & Revenue Mix (H1 FY26 / Q1 FY26)** - **Serves over 400 customers** across **more than 60 countries**. - **Revenue Distribution (excl. real estate, H1FY26)**: - **India**: 40% - **Europe**: 29% - **North America**: 13% - **Other Regions**: 18% - **Trend**: Gradual internationalization, with India’s share declining from 43% (Q1 FY25) to 35% (Q1 FY26), while Europe and North America show positive momentum (+7pp and +3pp respectively). --- ### **Strategic Subsidiaries & Global Reach** - **Fermenta USA LLC** (Texas): - Acquired 52% stake in AGD Nutrition (2020), rebranded in 2020. - Focus: **Human and animal nutrition distribution** in the largest nutraceutical market. - Targeting major retailers (Walmart, CVS, Walgreens) with vitamin raw materials. - **Fermenta Biotech GmbH** (Germany, Hamburg): - Enables **local feed-grade Vitamin D3 powder production** via toll manufacturing. - Strengthens European market access and offers “**Made in Europe**” advantages. - **Distribution Partnerships**: - **Kappa Bioscience**: Exclusive distributor for select **Vitamin K2** variants in India. - **Atacama Bio (Chile)**: Exclusive distributor for **NatAxtin® (natural astaxanthin)** in human nutrition and aquaculture. - **Golden Omega (Chile)**: Exclusive distributor of high-purity **Omega-3** products in Indian subcontinent. --- ### **Key Strategic Developments (2020–2025)** - **2020**: - Merger of DIL and Fermenta Biotech completed. - Backward integration into **cholesterol production** (key Vitamin D3 raw material). - **2021**: - Acquisition of **AGD Nutrition LLC** (US) to strengthen North American presence. - Commercial launch of **fish oil-derived cholesterol** for aquaculture. - **2022**: - Launch of **Vitamin AD2** for oil fortification. - Feed-grade Vitamin D production begins in **Germany**. - **2023–2024**: - Commissioning of **FRK plant** (Tirupati) and **customized premix plant** (Kullu). - Filing of **patents for VITADEE™ Green (plant-based D3)**. - **2025**: - **CEP certification** for spray-dried Vitamin D3 (Kullu). - **Slump sale of environmental business** to FESPL to sharpen focus and drive specialization. - Strategic shift toward **clean-label, value-added nutritional formats**. --- ### **Innovation & Intellectual Property** - **Patents**: - Proprietary process for **plant-based Vitamin D3 (VITADEE Green)**. - Enzymatic synthesis of **Molnupiravir** and **Vitamin K1**. - **Fermsept®** for bioremediation. - **Green Chemistry Leadership**: - Replaces hazardous processes with **enzymatic, sustainable routes**, reducing solvent use, energy, and waste. - Positioned as a **strategic innovation partner**, not just a supplier. --- ### **Customer & Market Strategy** - **Diversified Customer Base**: - Serves **400+ customers** globally. - **Low concentration risk**: Largest customer ≤ 9% revenue; top 5 account for 25%. - **High-Value Clients**: - 11 customers generate INR 5–15 crore annually. - 2 customers contribute > INR 15 crore, indicating strong B2B client relationships. - **Focus Areas**: - **Preventive health**, **fortified foods**, **clean-label trends**, and **functional nutrition**. - Expanding into **medical nutraceuticals** and **B2B nutrition ingredients**. --- ### **Financial Highlights (FY23)** - **Consolidated Revenue**: ₹481 Crore. - **Nutrition Business**: 73% (₹351 Crore), with **Human Vitamin D3** as top contributor (₹216 Crore). - Real estate value unlocking and non-core assets contributed ₹67 Crore. *(Note: Updated FY25 revenue mix reflects shift—India 40%, Europe 27%, North America 17%).* --- ### **Management & Leadership** - **Managing Director**: Over 30 years in pharma, with deep expertise in APIs and R&D. - **Executive Director (Anupama Datla Desai)**: Led transformation since 2006; oversees R&D, innovation, and strategic growth. - Leadership emphasizes **science-driven, sustainable innovation** and **capital-efficient expansion**. --- ### **Investment Highlights** - **Proven Innovator**: First-mover in vegan Vitamin D3, immobilized enzymes, and plant-based APIs. - **Non-China Supply Chain**: Strategic advantage in a global market vulnerable to sourcing risks. - **Regulatory Credibility**: Certified by **EDQM, US FDA, EU GMP, FSSC 22000, BRC, WHO-GMP, FAMI-QS**. - **Sustainable & Scalable Model**: Backward integration, low customer concentration, diversified geographies. - **High Growth Segments**: Nutraceuticals, food fortification, green chemistry, and sustainable nutrition.